The socioeconomic impact of hepatitis C infection and liver transplantation in Mexico

Annals of Hepatology

Volumn 11, Issue 4, 2012, Pages 550-551

  Méndez Sánchez, Nahum ^a  

^a LIVER RESEARCH UNIT   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PEGINTERFERON; RIBAVIRIN; TELAPREVIR; ANTIVIRUS AGENT;

AGE DISTRIBUTION; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; EDITORIAL; HEALTH CARE COST; HEALTH CARE DISTRIBUTION; HEPATITIS C; HIGH RISK POPULATION; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MEXICO; MORBIDITY; OUTCOME ASSESSMENT; PREVALENCE; PUBLIC HEALTH PROBLEM; RECURRENT VIRUS INFECTION; SOCIAL STATUS; SOCIOECONOMICS; TREATMENT INDICATION; TREATMENT RESPONSE; COST BENEFIT ANALYSIS; COST CONTROL; DISEASE COURSE; DRUG COST; ECONOMICS; HEALTH CARE DELIVERY; LIVER CELL CARCINOMA; LIVER TUMOR; VIROLOGY;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COST SAVINGS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG COSTS; HEALTH CARE COSTS; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MEXICO; PREVALENCE; SOCIOECONOMIC FACTORS;

EID: 84862011031     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31470-x     Document Type: Editorial

References (13)

1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-15.
2. Valdespino JL, Conde-Gonzalez CJ, Olaiz-Fernández G, et al. Seroprevalencia de Ia hepatitis C en adultos de Mexico: ¿un problema de salud pública emergente? Sal Pub Mex 2007; 49: 395-403.
3. Méndez-Sanchez N, Gutiérrez-Grobe Y, Kobashi Margáin RA. Epidemiology of HCV infection in Latin America. Ann Hepatol 2010; 9(Suppl.): 27-9.
4. Censo de Población y Vivienda de Mexico 2010. Available from: www.inegi.org.mx
5. Keeffe EB. Liver transplantation: current status and novel approaches to liver replacement. Gastroenterology 2001; 120: 749-62.
6. Thomas DL. Advances in the treatment of hepatitis C virus infection. Top Antivir Med 2012; 20: 5-10.
7. Poordad F, McCone J Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl Med 2011; 364: 1195-206.
8. Jacobson IM, McHutchinson, JG, Dusheiko G, et al. Tele previr in combination with Peginterferon and Ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis C. N Engl J Med 2011; 364: 2405-16.
9. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
10. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997; 25: 754-8.
11. Lee CM, Lu SN, Hung CH, Tung WC, Wang JH, Tung HD, et al. Hepatitis C virus genotypes in southern Taiwan: prevalence and clinical implications. Trans R Soc Trop Med Hyg 2006; 100: 767-74.
12. U.S. & World Population Clocks. http://www.census.gov/ main/www/popclock.html. [Accessed April 17,2012].
13. Cammá C, Petta S, Enea M, Bruno R, Bronte F, Capursi V, Cicchetti A, Colombo GL, et al; on behalf of the WEF Study Group. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2012. Doi: 10.1002/hep.25734 [Epub ahead of print].